Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially.
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Both systolic blood pressure and lowdensity lipoprotein (LDL) cholesterol show graded associations with cardiovascular disease and together account for two thirds of the population-attributable risk of cardiovascular disease. [2] [3] [4] Therefore, combined lowering of LDL cholesterol and blood pressure can potentially have a bigger effect in reducing cardiovascular events than either intervention alone. Because the majority of cardiovascular events occur in persons at average risk with no previous cardiovascular disease, a strategy of broad population-based treatment of LDL cholesterol and blood pressure could be more effective than targeting only high-risk persons. 5 These considerations form the basis for the polypill concept, which theorizes large reductions in cardiovascular events with systematic use of combination-drug therapy in middle-aged and older persons in the general population. 6, 7 We therefore evaluated the effects of a moderate dose of a potent statin (without lipid monitoring) versus placebo, a fixed combination of moderate doses of an angiotensin-receptor blocker plus a diuretic (without blood-pressure targets) versus placebo, and the combination of both treatments versus dual placebo on the prevention of major cardiovascular events. This report focuses on the efficacy and safety of the combination of LDL cholesterol lowering and blood-pressure lowering versus placebo.
Me thods

Trial Design and Oversight
The Heart Outcomes Prevention Evaluation (HOPE)-3 trial is a multicenter, long-term, international, double-blind, randomized, placebo-controlled trial with a 2-by-2 factorial design. We evaluated cholesterol lowering with rosuvastatin versus placebo, blood-pressure lowering with a combination of candesartan and hydrochlorothiazide versus placebo, and the combination of lipid and blood-pressure lowering versus dual placebo in preventing cardiovascular events among persons who did not have cardiovascular disease and who were at intermediate risk (defined as an annual risk of major cardiovascular events of approximately 1%) 8 (Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). The results of the blood-pressure-lowering analysis and the lipid-lowering analysis are reported in accompanying articles in the Journal. 9, 10 A detailed description of the trial methods is provided in the article that focuses on the effects of blood-pressure lowering.
The trial was designed by the steering committee who, along with staff at the Population Health Research Institute, oversaw the conduct of the trial, the collection and analysis of the data, and the interpretation of the results. The first author along with three other authors from the Population Health Research Institute had full access to the data and vouch for the accuracy and completeness of the data and analysis and for the fidelity of this report to the protocol. The first author drafted the manuscript, and all the authors made the decision to submit the manuscript for publication. Funding was provided by the Canadian Institutes of Health Research and AstraZeneca. AstraZeneca provided the trial drug, served as a single voting member on the 24-member steering committee, and had no other role in the trial. The trial was conducted at 228 centers in 21 countries and received regulatory and ethics approval for each participating site or from a central board that provided approval for multiple sites. All participants provided written informed consent.
Eligibility
The trial included men 55 years of age or older and women 65 years of age or older without cardiovascular disease and with at least one additional risk factor besides age (Table S2 in the Supplementary Appendix). We also included women 60 years of age or older who had at least two such risk factors. Persons with cardiovascular disease and those with an indication for or contraindication to statins, angiotensin-receptor blockers, angiotensin-converting-enzyme inhibitors, or thiazide diuretics were excluded. The trial did not mandate specific lipid or bloodpressure levels for entry. Fasting lipid and glucose levels were measured locally to inform physicians about participants' risks, but trial eligibility was based on the uncertainty principle: only those with clear indications for or contraindications to trial drugs, according to the judgment of the local physician and taking into account local guidelines and standards of practice, were excluded from participation. 
Trial Procedures
Eligible persons entered a single-blind run-in phase, during which they received both active treatments (for blood-pressure lowering and for cholesterol lowering) for 4 weeks. Participants who adhered to the regimen and who did not have an unacceptable level of adverse events were randomly assigned to a fixed combination of candesartan (16 mg per day) and hydrochlorothiazide (12.5 mg per day) or placebo and to rosuvastatin (10 mg per day) or placebo. Follow-up visits occurred at 6 weeks and 6 months after randomization and every 6 months thereafter. Individualized structured lifestyle advice was provided, on the basis of identified needs, and blood pressure was recorded at each visit in the first year and then annually. Lipid levels were measured at baseline in all participants and at 1 year, at 3 years, and at the end of the trial in 10 to 20% of the participants (with representation across geographic areas and racial and ethnic groups) (see the Supplementary Appendix for further information). Open-label statins could be prescribed at the physicians' discretion, in which case trial rosuvastatin or placebo was discontinued.
Outcomes
All cardiovascular events and cases of new-onset diabetes were documented and adjudicated (see the Supplementary Appendix). There were two coprimary outcomes: the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (first coprimary outcome) and the composite of these events plus resuscitated cardiac arrest, heart failure, or revascularization (second coprimary outcome). The secondary outcome was the composite of events comprising the second coprimary outcome plus angina with evidence of ischemia. This outcome was adopted by the steering committee on July 15, 2015, with no protocol amendment before unblinding of the data on November 3, 2015. At that time, a prespecified renal outcome was removed owing to limitations of statistical power. Additional prespecified outcomes included death from any cause, the components of the coprimary outcomes, new-onset diabetes, cognitive function (in participants ≥70 years of age), and erectile dysfunction in men. The latter two outcomes are not reported here. Safety reporting is described in the Supplementary Appendix.
Statistical Analysis
With an expected annual event rate of 1% for the first coprimary outcome in the dual-placebo group, an average duration of follow-up of 5.5 years, cumulative nonadherence rates of 23%, drop-in rates of 11%, and rates of loss to follow-up of less than 1%, we estimated that a sample of 12,700 participants (of whom 6348 would be randomly assigned to dual active treatment or dual placebo) would give the trial 80% power to detect a risk of the coprimary outcomes with combination therapy that was at least 35% lower than the risk with dual placebo. 8 No formal power calculations for this analysis were made for the comparisons of cholesterol lowering alone versus placebo, blood-pressure lowering alone versus placebo, or cholesterol lowering alone versus blood-pressure lowering alone.
The main analyses were performed according to the intention-to-treat principle. Survival curves were computed with the use of the Kaplan-Meier procedure. A Cox proportional-hazards model was used to estimate treatment effects and to evaluate effects in subgroups. No significant interaction between the two treatments was observed. The strategy used to preserve an overall type I error rate of 5% for the entire trial is described in the Supplementary Appendix; on the basis of this strategy, a nominal P value of less than 0.05 was used to test both coprimary outcomes in a comparison of the combined-therapy group with the dual-placebo group in the 6348 trial participants included in these two groups. Prespecified hypothesis-based subgroup analyses were conducted according to thirds of baseline risk (determined by the INTERHEART Risk Score), 12 of systolic blood pressure, and of LDL cholesterol concentration (with P values for trend). A post hoc recurrent-events analysis 13 was performed to describe the effect on the risk of total cardiovascular events.
R esult s
Trial Participants and Follow-up
A total of 12,705 participants who adhered to the regimen and did not have an unacceptable level of adverse events during the run-in period underwent randomization. Of these, 3180 were assigned to candesartan-hydrochlorothiazide plus rosuvastatin (combined therapy), 3181 to rosuvastatin plus placebo, 3176 to candesartan-hydro-n engl j med nejm.org
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Adherence to Trial Drugs
Among participants who were assigned to receive candesartan-hydrochlorothiazide and rosuvastatin, 83.6% were taking both trial medications at 2 years, and 74.6% were taking both at the end of the trial; the corresponding rates in the dualplacebo group were 83.3% and 71.8% (Table S5 in the Supplementary Appendix). In the combinedtherapy group, an additional 1.6% were taking rosuvastatin only at 2 years, and 2.9% were taking rosuvastatin only at the end of the trial; an * Plus-minus values are means ±SD. There were no significant differences in the baseline characteristics among the four groups. Data on blood pressure were missing for 2 participants in the dual-placebo group, and data on central core laboratory measurements of low-density lipoprotein (LDL) cholesterol concentration for 321 in the combined-therapy group, 335 in the rosuvastatin-plus-placebo group, 328 in the group assigned to candesartan-hydrochlorothiazide plus placebo, and 323 in the dual-placebo group. Data on age and sex were complete. Data on other characteristics were available for 99.7% or more of the trial participants, except that some laboratory variables measured at the central core laboratory had rates of missing data similar to that for LDL cholesterol concentration. Table S2 in the Supplementary Appendix. ‡ The body-mass index is the weight in kilograms divided by the square of the height in meters. § The scale of the INTERHEART Risk Score ranges from 0 to 49; low cardiovascular risk corresponds to a score of 9 or less, medium risk to a score of 10 to 15, and high risk to a score of 16 or more.
12 ¶ Race and ethnic group were determined by self-report. n engl j med nejm.org
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T h e ne w e ngl a nd jou r na l o f m e dicine additional 1.4% and 1.5% were taking candesartan-hydrochlorothiazide only at the respective visits. In the dual-placebo group, 1.2% of the participants were taking the rosuvastatin placebo only at 2 years and 1.6% were taking the rosuvastatin placebo only at the end of the trial; 1.9% and 3.5% of the participants, respectively, were taking the candesartan-hydrochlorothiazide placebo only at the two time points. The use of open-label and nontrial drugs is presented in Table S5 in the Supplementary Appendix.
Blood Pressure and Lipid Levels
On average over the course of the trial, the mean systolic blood pressure was lower by 6.2 mm Hg in the combined-therapy group than in the dualplacebo group, the mean diastolic blood pressure was lower by 3.2 mm Hg, and the mean LDL cholesterol level was lower by 33.7 mg per deciliter (0.87 mmol per liter) ( Fig. 1 ) (P<0.001 for all comparisons). The difference in blood pressure was similar for participants assigned to candesartan-hydrochlorothiazide alone versus placebo; the difference in LDL cholesterol level was similar for participants assigned to rosuvastatin alone versus placebo.
Clinical Outcomes
The first coprimary outcome occurred in 113 participants (3.6%) in the combined-therapy group and in 157 participants (5.0%) in the dual-placebo group (hazard ratio, 0.71; 95% confidence interval [CI], 0.56 to 0.90; P = 0.005; relative difference, 29%; absolute difference, 1.4 percentage points; number needed to treat to prevent one outcome event, 72) ( Table 2 , and Fig. S9 in the Supplementary Appendix). The second coprimary outcome occurred in 136 participants (4.3%) in the combined-therapy group and in 187 (5.9%) in the dual-placebo group (hazard ratio, 0.72; 95% CI, 0.57 to 0.89; P = 0.003; relative difference, 28%; absolute difference, 1.6 percentage points; number needed to treat, 63) ( Table 2 and Fig. 2A ). There were also significant between-group differences in the incidence of the secondary outcome (147 participants [4.6%] in the combinedtherapy group vs. 205 [6.5%] in the dual-placebo group; hazard ratio, 0.71; 95% CI, 0.57 to 0.87; P = 0.001) (Fig. S10 in the Supplementary Appendix) and in the incidence of any kind of stroke (31 participants [1.0%] vs. 55 [1.7%]; hazard ratio, 0.56; 95% CI, 0.36 to 0.87; P = 0.009). There were 163 deaths in the combined-therapy group and 178 in the dual-placebo group; there were fewer deaths from cardiovascular causes in the combined-group group than in the dual-placebo group (75 vs. 91), but no difference was seen in the number of deaths from other causes (88 and 87, respectively) (Table S18 in the Supplementary Appendix). In a post hoc analysis, there were fewer first and recurrent events of the first coprimary outcome with combined therapy than with dual placebo (hazard ratio, 0.68; 95% CI, 0.53 to 0.87; P = 0.002) and fewer first and recurrent events of the second coprimary outcome (hazard ratio, 0.66; 95% CI, 0.52 to 0.84; P = 0.001).
Subgroup Analyses
There were no significant treatment-by-subgroup interactions with respect to the first and second coprimary outcomes in the three prespecified subgroups defined according to stroke risk, LDL cholesterol level, and systolic blood pressure at baseline (Fig. S16 and S17 in the Supplementary Appendix). In a post hoc analysis of the first coprimary outcome comparing the upper third of systolic blood pressure (>143.5 mm Hg) with the lower two thirds, the point estimate for the hazard ratio was lower in the upper third (hazard ratio, 0.59; 95% CI, 0.40 to 0.85) than in the lower two thirds (hazard ratio, 0.82; 95% CI, 0.59 to 1.12), although the P value for interaction of 0.19 was not nominally significant. There was no significant heterogeneity in the effects of combination therapy in subgroups defined according to age, sex, or race or ethnic group.
Cholesterol Lowering Alone versus BloodPressure Lowering Alone
There was a nonsignificant trend toward a lower risk of the first coprimary outcome with rosuvastatin plus placebo than with candesartan-hydrochlorothiazide plus placebo (122 participants [3.8%] and 147 [4.6%], respectively; hazard ratio, 0.82; 95% CI, 0.65 to 1.05; P = 0.11) ( Table 2 ). There was a nominally significant difference in the risk of the second coprimary outcome (141 participants [4.4%] with rosuvastatin plus placebo vs. 176 [5.5%] with candesartan-hydrochlorothiazide plus placebo; hazard ratio, 0.79; 95% CI, 0.64 to 0.99; P = 0.04).
Muscle weakness and dizziness were more common in the combined-therapy group than in the dual-placebo group. The incidence of muscle weakness or pain was similar in the combinedtherapy group and the rosuvastatin-plus-placebo group, and the incidence of dizziness, lightheadedness, or hypotension was similar in the com- n engl j med nejm.org
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T h e ne w e ngl a nd jou r na l o f m e dicine Table 2 bined-therapy group and the group assigned to candesartan-hydrochlorothiazide plus placebo. The rates of permanent discontinuation for any reason did not differ significantly between the combined-therapy group and the dual-placebo group (26.3% and 28.8%, respectively), nor did the rates of serious adverse events. (For more on safety outcomes, see Tables S19 through S23 in the Supplementary Appendix.)
Discussion
In the HOPE-3 trial, which involved a primary prevention population at intermediate risk and with average lipid and blood pressure levels, combination therapy with rosuvastatin (10 mg per day), candesartan (16 mg per day), and hydrochlorothiazide (12.5 mg per day) for a median of 5.6 years was associated with a significantly lower risk of cardiovascular events than dual placebo (29% lower relative risk and 1.4-percentage-point lower absolute risk of the first primary outcome). The number needed to treat for 5.6 years to prevent one event of the first coprimary outcome was 72, and the number needed to treat to prevent one event of the second coprimary outcome was 63. In a post hoc recurrent-events analysis, the benefit was slightly larger. The reduction in LDL cholesterol concentration was approximately 33.7 mg per deciliter over the course of the trial (which is similar to the 38.6 mg per deciliter [1.00 mmol per liter] that was expected), 8 and the reduction in systolic blood pressure was 6.2 mm Hg (which is lower than the expected 8 mm Hg reduction). Rates of adherence to rosuvastatin and to candesartan-hydrochlorothiazide were high, and so the degree of cholesterol and blood-pressure lowering that we observed, in a large population treated over a median of 5.6 years, is probably more representative than that observed in small, short-term trials involving persons with elevated blood pressure or high lipid levels. Greater reductions in LDL cholesterol and in systolic blood pressure could be achieved with a more intensive regimen, and the reductions in cardiovascular outcomes could be larger, 14, 15 but the safety of such an approach would need to be established.
We performed a post hoc subgroup analysis comparing participants in the upper third of baseline systolic blood pressure with those in the lower two thirds. Among participants in the upper third, the risk of the two coprimary outcomes was approximately 40% lower with combined therapy than with dual placebo, whereas the relative risk was only about 20% lower among participants with lower systolic blood pressure. Although the test for interaction between these two effects was not significant, these results (comparing combined therapy with dual placebo) are based on only half the entire trial cohort. In the overall trial, a significant treatment-by-subgroup interaction was seen according to thirds of baseline systolic blood pressure for the comparison of candesartan-hydrochlorothiazide with placebo; only those in the highest third of systolic blood pressure benefited from treatment to lower blood pressure. 10 These results are consistent with those of two metaanalyses of trials of blood-pressure lowering, which showed that there was a clear benefit of antihypertensive therapy in persons with a systolic blood pressure of 140 mm Hg or more but no benefit on cardiovascular events (as a composite) in those with an initial systolic blood pressure of less than 140 mm Hg. 16, 17 By contrast, the effects of rosuvastatin in the HOPE-3 trial were independent of blood-pressure or lipid levels. These different lines of evidence suggest that combination therapy (with a statin and blood-pressure-lowering treatment) would perform best in persons with elevated blood pressure, whereas statins alone would perform best in those without elevated blood pressure.
We also found that the rate of myocardial infarction was lower in the combined-therapy group than in the placebo group (relative difference, 45%; absolute difference, 0.5 percentage points), as was the rate of stroke (relative difference, 44%; absolute difference, 0.8 percentage points). These estimates are similar to those from the Anglo-Scandinavian Cardiac Outcomes Trial 18 with combined lipid and blood-pressure lowering (albeit with a different regimen for blood-pressure lowering) but were substantially lower than the 80% relative risk reduction projected by Wald and Law for the effect of a polypill (consisting of three blood-pressure-lowering agents, a statin, folate, and aspirin). 6 We did not use three blood-pressure-lowering drugs together because of limited data on long-term safety in persons without hypertension. Aspirin was not used because its role in primary prevention is unclear, 19 and trials of folate in Western countries have been disappointing 20 (although in a recent trial in China, where dietary folate intake is low, stroke rates were reduced 21 ). There were no significant differences between the combined-therapy group and the dualplacebo group in the rate of new-onset diabetes, renal dysfunction, syncope, liver-function abnormalities, eye problems, or cancers. Although the rates of muscle weakness or pain and of dizziness were higher in the combined-therapy group than in the dual-placebo group (by 0.9 percentage points and 2.2 percentage points, respectively), these effects were reversible by temporary dis- continuation of the trial drug. There was only one case of rhabdomyolysis (in the rosuvastatinplus-placebo group), which was detected clinically, indicating that there is little need for routine blood testing with a combined-treatment strategy. Furthermore, our approach of selecting persons on the basis of age and easily measured risk factors means that neither complex screening nor blood tests are required to initiate treatment with low doses of combination therapy. Our trial included persons of diverse racial and ethnic groups from 21 countries with broadly consistent benefits and safety.
In conclusion, in the HOPE-3 trial, treatment with fixed doses of rosuvastatin and two antihypertensive agents was associated with a significantly lower risk of cardiovascular events than the risk with placebo among intermediate-risk persons without previous cardiovascular disease.
